Canadian cannabis producer Cronos Group reported a quarterly loss of $111.7 million and an adjusted EBITDA of negative $53.1 million, according to the full-year and fourth-quarter results released Friday, well below analyst expectations. However, Crono…
Cronos
Will GW’s multibillion-dollar sale ‘open floodgates’ to pharma-cannabis deal-making?
Jazz Pharmaceuticals’ planned $7.2 billion takeover of United Kingdom-based GW Pharmaceuticals could kick off a wave of deal-making between pharma and medical cannabis companies, analysts and industry sources say. But rather than all cannabis pro…
Will GW’s multibillion-dollar sale ‘open floodgates’ to pharma-cannabis deal-making?
Jazz Pharmaceuticals’ planned $7.2 billion takeover of United Kingdom-based GW Pharmaceuticals could kick off a wave of deal-making between pharma and medical cannabis companies, analysts and industry sources say. But rather than all cannabis pro…
Cannabis producer Cronos halves loss to $68 million on higher revenue
Canadian cannabis producer Cronos Group reported improved revenue for its latest quarter, but a bottom line that remains in the red. The Toronto-based company reported a net loss of $68 million for the third quarter ended Sept. 30, compared to a $107 m…